Promedius

Promedius has developed an AI-powered software, PROS® CXR: OSTEO, that analyzes chest X-ray images to screen for individuals at risk of osteoporosis. This approach provides an accessible and cost-effective alternative to the standard diagnostic method, dual-energy X-ray absorptiometry (DXA), which has limited availability. By identifying at-risk individuals early, the technology facilitates timely DXA testing and treatment, aiming to prevent fractures. The software, which received clearance from the Korean Ministry of Food and Drug Safety in 2025, automatically analyzes radiographs and generates reports for both clinicians and patients. The company's business model targets healthcare providers, including primary care clinics and medical facilities, by offering its AI solutions to bridge gaps in medical resources. Strategic collaborations with major DXA equipment manufacturers and pharmaceutical companies specializing in osteoporosis treatments are a key component of its global expansion strategy.

The company has secured significant funding to support its growth. In March 2024, Promedius closed a Series A2 investment round of $8.5 million (11.2 billion won), bringing its total cumulative funding to over $10.8 million (13.6 billion won). The round was led by Stassets Investment and included participation from Korea Investment Partners, Woori Venture Partners, Crit Ventures, DK Medical, and Big Move Ventures. This followed a Series A1 round in 2021 and selection for the TIPS R&D program by the Ministry of SMEs and Startups in 2020. Milestones include obtaining 24 patents by 2022 and starting research collaborations with prominent institutions like Massachusetts General Hospital and Seoul National University Hospital in 2023.